News
Resources
Blog
Sites
Recent Posts
Medicare Monday: A closer look at Medicare Part B
By Kelsey Lang | January 16, 2017
We took a deeper dive on Medicare Part D last week, so today we’re switching gears and talking about Medicare Part B.
Read More
Medicare Monday: New research finds trends in Average Sales Price of Part B drugs remains stable
By Kelsey Lang | December 19, 2016
Earlier this year, we looked at Average Sales Price (ASP) and how it works in Medicare Part B. As you may remember, ASP (the method for reimbursing drugs covered by Part B) is a market-based price...
Read More
Medicare Monday: How existing CMMI models affect Medicare Part B
By Kelsey Lang | November 7, 2016
Earlier this year the Center for Medicare & Medicaid Innovation (CMMI) proposed the Medicare Part B Drug Payment Model, also known as the Part B Demo, an experiment that would change how providers...
Read More
In the more than 1,300 comments submitted to the Centers for Medicare & Medicaid Services (CMS) on the Part B Drug Payment Model, a wide range of organizations raised concern with the unprecedented...
Read More
We’ve highlighted how the proposed Part B model lacks safeguards to protect patients from barriers and reduced quality of care. Some stakeholders have suggested that the Part B proposal looks a lot...
Read More
New Research: Access and quality implications of CMS proposed Part B model
By Kelsey Lang | April 27, 2016
In recent weeks, providers and stakeholders across the health care system have raised concerns that the Part B Drug Payment Model proposed by the Centers for Medicare & Medicaid Services (CMS) lacks...
Read More
Medicare Monday: Provider consolidation drives up costs for patients and government
By Kelsey Lang | April 18, 2016
Two recent studies add to a growing body of research on how consolidation is driving up treatment costs. More and more cancer treatments are being administered at hospital outpatient facilities...
Read More
ICYMI: American Society for Clinical Oncology statement on clinical pathways
By Kelsey Lang | January 18, 2016
Last week, the American Society for Clinical Oncology (ASCO) issued a policy statement calling for improvements in clinical pathway programs. The statement responds to the growing concern that...
Read More
Medicare Monday: Part B and biosimilars, part 2
By Kelsey Lang | November 30, 2015
Earlier this month, Medicare Monday covered the Center for Medicare & Medicaid Services (CMS) final rule on reimbursement for biosimilars and the implications of using a single billing code to...
Read More
Medicare Monday: New research finds drugs not a key driver of Medicare Part B costs
By Kelsey Lang | October 26, 2015
Over the last several weeks, Medicare Monday has talked about services covered by Medicare Part B and average sales price (ASP), the method for reimbursing drugs covered by Part B. In particular,...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
